Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Jackson Heart Clinic

Neither a doctor nor a teaching hospital

Research payments

$863,742

81 payments

Through program year 2025, Jackson Heart Clinic is reported as receiving $863,742 in research payments, across 81 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $43,496 6
2024 Research $35,924 3
2023 Research $50,004 12
2022 Research $272,667 7
2021 Research $241,680 22
2020 Research $135,897 23
2019 Research $84,074 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $596,311 20 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $206,859 22 payments
  3. Amgen Inc. $29,183 5 payments
  4. Boehringer Ingelheim International GmbH $10,826 25 payments
  5. TriReme Medical LLC $10,550 4 payments
  6. Philips Electronics North America Corporation $5,000 1 payment
  7. Boehringer Ingelheim Pharma GmbH & Co.KG $3,558 1 payment
  8. Daiichi Sankyo Inc. $1,455 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Prospective Comparison of Arni With Arb Given Following Stabilization in Decompensated Hfpef (Paraglide-Hfpef) $373,611 4 payments
  2. Bmad $66,339 4 payments
  3. Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor Arni Versus Ace Inhibitor Trial to Determine Impact on Serious Events After Myocardial Infarction Paradise Mi $61,483 3 payments
  4. Maps $54,700 2 payments
  5. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $52,706 2 payments
  6. A Randomized, Controlled, Multicenter, Open-Label Trial Comparing A Post-Discharge Care Pathway Involving Aggressive LDL-C Management With Inclisiran With Usual Care in Patients With A Recent Acute Coronary Syndrome $50,302 4 payments
  7. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $38,469 3 payments
  8. Heart Failure Optimization Study $33,390 2 payments
  9. HF Opt $27,880 5 payments
  10. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) $23,778 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record